# A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors

> **NCT02162719** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 124 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Ipatasertib
- **DRUG:** Paclitaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02162719
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-19
- **Primary completion:** 2016-06-07
- **Final completion:** 2019-08-31
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2021-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02162719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02162719, "A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02162719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*